200 related articles for article (PubMed ID: 34118179)
1. First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers.
Rein-Hedin E; Sjöberg F; Waters S; Sonesson C; Waters N; Huss F; Tedroff J
Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1485-1494. PubMed ID: 34118179
[TBL] [Abstract][Full Text] [Related]
2. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
3. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong FJ; Zhao R; Zeng S; Magnusson B; Diagana TT; Pertel P
Antimicrob Agents Chemother; 2014 Nov; 58(11):6437-43. PubMed ID: 25136017
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
[TBL] [Abstract][Full Text] [Related]
5. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong FJ; Li R; Jain JP; Lefèvre G; Magnusson B; Diagana TT; Pertel P
Antimicrob Agents Chemother; 2014 Oct; 58(10):6209-14. PubMed ID: 25114127
[TBL] [Abstract][Full Text] [Related]
6. A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects.
Hernández-Mitre MP; Wallis SC; Morgan EE; Dudley MN; Loutit JS; Griffith DC; Roberts JA
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0109923. PubMed ID: 38059635
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects.
Nirogi R; Benade V; Goyal VK; Pandey SK; Mohammed AR; Shinde A; Dogiparti D; Ravula J; Jetta S; Palacharla VRC
Clin Drug Investig; 2022 Sep; 42(9):747-762. PubMed ID: 35963959
[TBL] [Abstract][Full Text] [Related]
11. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
Kansagra KA; Parmar D; Jani RH; Srinivas NR; Lickliter J; Patel HV; Parikh DP; Heading H; Patel HB; Gupta RJ; Shah CY; Patel MR; Dholakia VN; Sukhadiya R; Jain MR; Parmar KV; Barot K
Clin Pharmacokinet; 2018 Jan; 57(1):87-102. PubMed ID: 28508936
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
Han K; Cremer J; Elston R; Oliver S; Baptiste-Brown S; Chen S; Gardiner D; Davies M; Saunders J; Hamatake R; Losos J; Leivers M; Hood S; van der Berg F; Paff M; Ritter JM; Theodore D
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):790-801. PubMed ID: 30861337
[TBL] [Abstract][Full Text] [Related]
15. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
Weisel K; Scott NE; Tompson DJ; Votta BJ; Madhavan S; Povey K; Wolstenholme A; Simeoni M; Rudo T; Richards-Peterson L; Sahota T; Wang JG; Lich J; Finger J; Verticelli A; Reilly M; Gough PJ; Harris PA; Bertin J; Wang ML
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226626
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects.
Eckburg PB; Lister T; Walpole S; Keutzer T; Utley L; Tomayko J; Kopp E; Farinola N; Coleman S
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262767
[TBL] [Abstract][Full Text] [Related]
17. The randomized, single- and multiple- ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects.
Jing S; Liu W; Yang K; Lin Y; Yao X; Sun G
Clin Transl Sci; 2023 Mar; 16(3):447-458. PubMed ID: 36495036
[TBL] [Abstract][Full Text] [Related]
18. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.
Turncliff R; DiPetrillo L; Silverman B; Ehrich E
Clin Ther; 2015 Feb; 37(2):338-48. PubMed ID: 25456560
[TBL] [Abstract][Full Text] [Related]
19. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
